Thailand urged to end HIV drug "discrimination"

10 December 2007

Human Rights Watch, an international campaign group, has protested against what it terms "discrimination against [narcotic] drug users seeking health care services," which includes access to antiretroviral treatments in Thailand.

Although the country is under a military-backed government until elections scheduled for December 23, the human rights group argues that the problem dates from the previous government of Thaksin Shinawatra. At least 2,500 narcotics users were allegedly the victims of extrajudicial killings as a result of a "War on Drugs" program.

As a consequence of repressive policies, the Thai government estimates that 40%-50% of injectable narcotics users are HIV positive. This figure, unlike the successes in preventing infections in the rest of the population, has remained constant in the past 20 years, Human Rights Watch claims.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight